ED
MIRM icon

Exane Derivatives’s Mirum Pharmaceuticals MIRM Stock Holding History

Exane Derivatives’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,999
Closed -$179K – 931
2021
Q3 		$179K Buy
8,999
+373
+4% +$6.07K 0.04% 417
2021
Q2 		$138K Buy
+8,626
New +$155K 0.03% 500

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Exane Derivatives's MIRM Position: Q4 2021 in Review

Exane Derivatives sold out of Mirum Pharmaceuticals (MIRM) in Q4 2021, closing a stake of 8,999 shares — an estimated $179K sold.

Exane Derivatives first reported a position in MIRM in Q2 2021 and held it in 2 quarters. The position peaked at $179K in Q3 2021. 86 funds tracked by Wall St. Rank hold MIRM as of Q4 2021.

  • Exane Derivatives reported no remaining Mirum Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Exane Derivatives sold 8,999 Mirum Pharmaceuticals shares in Q4 2021, an estimated $179K.
  • Exane Derivatives first reported a position in Mirum Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Exane Derivatives's Mirum Pharmaceuticals position peaked at $179K in Q3 2021.
  • 86 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.